会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • MODULATION OF INFLUENZA VIRUS
    • 流感病毒调控
    • WO2010019712A1
    • 2010-02-18
    • PCT/US2009/053612
    • 2009-08-12
    • THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIADEGRADO, William, F.STOUFFER, Amanda, L.ACHARYA, RudreshSALOM-ARBONA, DavidPOLISHCHUK, Alexei
    • DEGRADO, William, F.STOUFFER, Amanda, L.ACHARYA, RudreshSALOM-ARBONA, DavidPOLISHCHUK, Alexei
    • C40B30/02
    • G06F19/706G06F19/16
    • The present invention provides, among other things, methods for the identification of compounds that are capable of modulating the activity of the influenza A virus. For example, the present methods provide platforms for identifying small molecule inhibitors that target the proton transport pathway defined at least in part by two or more of the highly conserved channel residues 27, 30, 31, 34, 37, 41, 44, and 45 of the influenza A M2 protein. In one aspect, the present invention is directed to methods comprising comparing spatial models of a plurality of test compounds with the spatial model of the pathway defined by at least two residues from among residues 27, 30, 31, 34, 37 or 41, 44, and 45 on one or more subunits of the M2 transmembrane protein of the influenza A virus to determine the spatial complementarity of each of the test compounds with the pathway; assessing the ability of the test compounds to bind to the pathway; and, based on the assessed ability of the test compounds to bind the pathway, determining the compound that modulates the activity of influenza A.
    • 本发明尤其提供了用于鉴定能够调节甲型流感病毒活性的化合物的方法。 例如,本方法提供用于鉴定靶向至少部分由两个或更多个高度保守通道残基27,30,31,34,37,41,44和45定义的质子转运途径的小分子抑制剂的平台 的流感A M2蛋白。 在一个方面,本发明涉及包括将多个测试化合物的空间模型与由残基27,30,31,34,37或41,44中的至少两个残基限定的途径的空间模型进行比较的方法 和45个在甲型流感病毒的M2跨膜蛋白的一个或多个亚基上,以确定每种测试化合物与途径的空间互补性; 评估测试化合物结合途径的能力; 并且基于测试化合物结合途径的评估能力,确定调节流感A的活性的化合物。
    • 6. 发明申请
    • COMPUTATIONAL DESIGN OF A WATER-SOLUBLE ANALOG OF A PROTEIN, SUCH AS PHOSPHOLAMBAN AND POTASSIUM CHANNEL KCSA
    • 蛋白质水溶性模拟物的计算设计,如磷酰胺和钾通道KCSA
    • WO2004065363A2
    • 2004-08-05
    • PCT/US2004/001317
    • 2004-01-21
    • THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIASAVEN, Jeffrery, G.DEGRADO, William, F.SLOVIC, Avram, M.SUMMA, Christopher, M.KONO, Hidetoshi
    • SAVEN, Jeffrery, G.DEGRADO, William, F.SLOVIC, Avram, M.SUMMA, Christopher, M.KONO, Hidetoshi
    • C07D
    • G06F19/16G06F19/18
    • Membrane proteins and water-soluble proteins share a similar core. This similarity suggests that it should be possible to water-solubilize membrane proteins by mutating only their lipid-exposed residues. Computational tools and methods are disclosed herein that can be used to design water-soluble variants of helical membrane proteins, using the pentameric phospholamban (PLB) and potassium channel KcsA as models. To water-solublize PLB, the membrane-exposed positions were changed to polar or charged amino acids, while the putative core was left unaltered. We generated water-soluble phospholamban (WSPLB), and compared its properties to its predecessor PLB. As a probe of the correctness of the fold of the water soluble KcsA, the computationally designed proteins contain an agitoxin-2 binding site from a mammalian homologue of the channel. The resulting proteins express in high yield in E. coli and share the intended functional and structural properties with KcsA, including secondary structure, tetrameric quaternary structure, and tight, specific binding to both agitoxin2 and a small molecule channel blocker.
    • 膜蛋白和水溶性蛋白质共享相似的核心。 这种相似性表明,应该可以通过仅突变其暴露于脂质的残留物来水溶性膜蛋白。 本文公开了可用于设计螺旋膜蛋白质的水溶性变体的计算工具和方法,其使用五聚磷酸甘油(PLB)和钾通道KcsA作为模型。 为了水解PLB,将膜暴露的位置改为极性或带电荷的氨基酸,而假定的核心保持不变。 我们产生了水溶性磷脂蛋白(WSPLB),并将其性能与其前身PLB进行了比较。 作为水溶性KcsA的倍数的正确性的探针,计算设计的蛋白质含有来自哺乳动物同源物的通道的搅拌毒素-2结合位点。 所得蛋白质在大肠杆菌中以高产率表达,并且与KcsA共享预期的功能和结构性质,包括二级结构,四聚体四级结构,以及紧密的,特异性结合于vibroxin2和小分子通道阻断剂。